Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
研究单位：[1]Merck Sharp & Dohme LLC[2]Afflilated Hospital of Bengbu Medical College-Surgical Oncology (Site 0638),Bengbu,Anhui,China,233004[3]Beijing Friendship Hospital ( Site 0637),Beijing,Beijing,China,100050[4]Beijing Cancer Hospital ( Site 0221),Beijing,Beijing,China,100142[5]Fujian Medical University Union Hospital-1 Bingfanglou-Gastric Surgery Department (Site 0632),Fuzhou Fujian,Fujian,China,350001[6]Fujian Provincial Cancer Hospital ( Site 0230),Fuzhou,Fujian,China,350014[7]The First Affiliated Hospital, Sun Yat-sen University (Site 0635),Guangzhou,Guangdong,China,510080[8]The First Affiliated Hospital of Guangzhou Medical University ( Site 0224),Guangzhou,Guangdong,China,510120[9]Fourth Hospital of Hebei Medical University ( Site 0633),Shijiazhuang,Hebei,China,050035[10]Henan Cancer Hospital (Site 0227),Zhengzhou,Henan,China,450008[11]The Affiliated Hospital of Xuzhou Medical College-Oncology ( Site 0645),Xuzhou,Jiangsu,China,221006[12]The First Hospital of Jilin University-Gastrointestinal Surgery ( Site 0234),Changchun,Jilin,China,130021[13]Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army ( Site 0647),Xi''an,Shaanxi,China,710038[14]Shandong Provincial Hospital-Gastrointestinal Surgery ( Site 0640),Jinan,Shandong,China,250001[15]The Affiliated Hospital of Qingdao University ( Site 0636),Qingdao,Shandong,China,266003[16]Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 0642),Shanghai,Shanghai,China,200127[17]Sichuan Cancer hospital,Chengdu,Sichuan,China,610041[18]Zhejiang Provincial People''s Hospital-Oncology (Site 0656),Hangzhou,Zhejiang,China,310014[19]Zhejiang Cancer Hospital ( Site 0231),Hangzhou,Zhejiang,China,310022[20]Sir Run Run Shaw Hospital ( Site 0233),Hangzhou,Zhejiang,China,430030[21]The First Affiliated Hospital of Wenzhou Medical University (Site 0652),Wenzhou,Zhejiang,China,32500
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma. No formal hypothesis testing will be done.
